Nisa Leung

Nisa Leung is founding Managing Partner at Aulis Capital. She served as Managing Partner at Qiming Venture Partners, where she founded and led the firm's healthcare practice since 2006. Nisa has been consistently recognized as one of the most influential investors in the industry. She has been featured on the Forbes Midas List for seven consecutive years (2019–2025). In 2024, she was honored as one of Fortune Asia’s Most Powerful Women (MPW Asia). She has invested in and served as a board director for numerous leading healthcare and life sciences companies, including Zai Lab (NASDAQ:ZLAB; HKSE:9688), Gan & Lee (SSE:603087), Cansino Biologics (SSE:688185; HKSE:6185), Insilico Medicine (HKSE:3696), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Schrödinger (NASDAQ:SDGR), Structure Therapeutics (NASDAQ:GPCR), Berry Genomics (SZSE:000710), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE:2607), Apollomics (NASDAQ:APLM), Crown Bioscience (acquired by JSR Life Sciences), Caidya, Belief BioMed, Alamar Biosciences (NASDAQ:ALMR), EpiBiologics, Aeira, Pluslife, Horizone, SinoUnited Health, Aeonmed, Novast, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), MedX, Goodwill (SSE:688246), Jacobio (HKSE:1167), Sesame Therapeutics, Hope Medicine, Chain Medical Labs, Sinotau, Zencore Biologics, Cognitact, Silicon Gene, Vision Pro, Thorough Future among many other groundbreaking companies in the life sciences and healthcare sectors globally. Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is visiting lecturer at Harvard Law School, a trustee of the Hotchkiss School, serves as a member of the Hong Kong University Court, Cornell University International Advisory Council and Stanford University International Advisory Council.